Cavin-1/PTRF alters prostate cancer cell-derived extracellular vesicle content and internalization to attenuate extracellular vesicle-mediated osteoclastogenesis and osteoblast proliferation

References

• Vela I, Gregory L, Gardiner EM, Clements JA, Nicol DL. Bone and prostate cancer cell interactions in metastatic prostate cancer. BJU Int. 2007; 99: 735–42. [PubMed Abstract].
   Google Scholar
• Thobe MN, Clark RJ, Bainer RO, Prasad SM, Rinker-Schaeffer CW. From prostate to bone: key players in prostate cancer bone metastasis. Cancers. 2011; 3: 478–93. [PubMed Abstract] [PubMed CentralFull Text].
   Google Scholar
• Gibbings DJ, Ciaudo C, Erhardt M, Voinnet O. Multivesicular bodies associate with components of miRNA effector complexes and modulate miRNA activity. Nature Cell Biol. 2009; 11: 1143–9. [PubMed Abstract].
   Google Scholar
• Kosaka N, Iguchi H, Yoshioka Y, Takeshita F, Matsuki Y, Ochiya T. Secretory mechanisms and intercellular transfer of microRNAs in living cells. J Biol Chem. 2010; 285: 17442–52. [PubMed Abstract] [PubMed CentralFull Text].
   Google Scholar
• Ohshima K, Inoue K, Fujiwara A, Hatakeyama K, Kanto K, Watanabe Y et al. Let-7 microRNA family is selectively secreted into the extracellular environment via exosomes in a metastatic gastric cancer cell line. PLoS One. 2010; 5: e13247. [PubMed Abstract] [PubMed CentralFull Text].
   Google Scholar
• Valadi H, Ekstrom K, Bossios A, Sjostrand M, Lee JJ, Lotvall JO. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nature Cell Biol. 2007; 9: 654–9. [PubMed Abstract].
   Google Scholar
• Record M, Carayon K, Poirot M, Silvente-Poirot S. Exosomes as new vesicular lipid transporters involved in cell-cell communication and various pathophysiologies. Biochim Biophys Acta. 2014; 1841: 108–20. [PubMed Abstract].
   Google Scholar
• Hood JL, Pan H, Lanza GM, Wickline SA. Consortium for Translational Research in Advanced I, Nanomedicine. Paracrine induction of endothelium by tumor exosomes. Lab Investig. 2009; 89: 1317–28. [PubMed Abstract] [PubMed CentralFull Text].
   Google Scholar
• Nazarenko I, Rana S, Baumann A, McAlear J, Hellwig A, Trendelenburg M et al. Cell surface tetraspanin Tspan8 contributes to molecular pathways of exosome-induced endothelial cell activation. Canc Res. 2010; 70: 1668–78.
   PubMed Web of Science ®Google Scholar
• Qu JL, Qu XJ, Zhao MF, Teng YE, Zhang Y, Hou KZ et al. Gastric cancer exosomes promote tumour cell proliferation through PI3K/Akt and MAPK/ERK activation. Dig Liver Dis. 2009; 41: 875–80. [PubMed Abstract].
   Google Scholar
• Singh PP, LeMaire C, Tan JC, Zeng E, Schorey JS. Exosomes released from M. tuberculosis infected cells can suppress IFN-gamma mediated activation of naive macrophages. PLoS One. 2011; 6: e18564. [PubMed Abstract] [PubMed CentralFull Text].
   Google Scholar
• Szajnik M, Czystowska M, Szczepanski MJ, Mandapathil M, Whiteside TL. Tumor-derived microvesicles induce, expand and up-regulate biological activities of human regulatory T cells (Treg). PLoS One. 2010; 5: e11469. [PubMed Abstract] [PubMed CentralFull Text].
   Google Scholar
• Peinado H, Aleckovic M, Lavotshkin S, Matei I, Costa-Silva B, Moreno-Bueno G et al. Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nat Med. 2012; 18: 883–91. [PubMed Abstract] [PubMed CentralFull Text].
   Google Scholar
• Tavoosidana G, Ronquist G, Darmanis S, Yan J, Carlsson L, Wu D et al. Multiple recognition assay reveals prostasomes as promising plasma biomarkers for prostate cancer. Proc Natl Acad Sci Unit States Am. 2011; 108: 8809–14.
   PubMed Web of Science ®Google Scholar
• Ronquist KG, Ronquist G, Larsson A, Carlsson L. Proteomic analysis of prostate cancer metastasis-derived prostasomes. Anticancer Res. 2010; 30: 285–90. [PubMed Abstract].
   Google Scholar
• Webber JP, Spary LK, Sanders AJ, Chowdhury R, Jiang WG, Steadman R. Differentiation of tumour-promoting stromal myofibroblasts by cancer exosomes. Oncogene. 2014 doi: 10.1038/onc.2013.560.
   Web of Science ®Google Scholar
• Abd Elmageed ZY, Yang Y, Thomas R, Ranjan M, Mondal D, Moroz K et al. Neoplastic reprogramming of patient-derived adipose stem cells by prostate cancer cell-associated exosomes. Stem Cell. 2014; 32: 983–97.
   PubMed Web of Science ®Google Scholar
• Inder KL, Zheng YZ, Davis MJ, Moon H, Loo D, Nguyen H. Expression of PTRF in PC-3 Cells modulates cholesterol dynamics and the actin cytoskeleton impacting secretion pathways. Mol Cell Proteomics. 2012; 11: 111 012245.
   Web of Science ®Google Scholar
• Moon H, Lee CS, Inder KL, Sharma S, Choi E, Black DM. PTRF/cavin-1 neutralizes non-caveolar caveolin-1 microdomains in prostate cancer. Oncogene. 2013 doi: 10.1038/onc.2013.315.
   Web of Science ®Google Scholar
• Nassar ZD, Moon H, Duong T, Neo L, Hill MM, Francois M et al. PTRF/Cavin-1 decreases prostate cancer angiogenesis and lymphangiogenesis. Oncotarget. 2013; 4: 1844–55. [PubMed Abstract] [PubMed CentralFull Text].
   Google Scholar
• Bastiani M, Liu L, Hill MM, Jedrychowski MP, Nixon SJ, Lo HP et al. MURC/Cavin-4 and Cavin family members form tissue-specific caveolar complexes. J Cell Biol. 2009; 185: 1259–73. [PubMed Abstract] [PubMed CentralFull Text].
   Google Scholar
• Sieh S, Lubik AA, Clements JA, Nelson CC, Hutmacher DW. Interactions between human osteoblasts and prostate cancer cells in a novel 3D in vitro model. Organogenesis. 2010; 6: 181–8. [PubMed Abstract] [PubMed CentralFull Text].
   Google Scholar
• Hill MM, Bastiani M, Luetterforst R, Kirkham M, Kirkham A, Nixon SJ et al. PTRF-Cavin, a conserved cytoplasmic protein required for caveola formation and function. Cell. 2008; 132: 113–24. [PubMed Abstract] [PubMed CentralFull Text].
   Google Scholar
• Kaighn ME, Narayan KS, Ohnuki Y, Lechner JF, Jones LW. Establishment and characterization of a human prostatic carcinoma cell line (PC-3). Invest Urol. 1979; 17: 16–23. [PubMed Abstract].
   Google Scholar
• Araujo JC, Poblenz A, Corn P, Parikh NU, Starbuck MW, Thompson JT et al. Dasatinib inhibits both osteoclast activation and prostate cancer PC-3-cell-induced osteoclast formation. Canc Biol Ther. 2009; 8: 2153–9.
   PubMed Web of Science ®Google Scholar
• Yuen HF, Chiu YT, Chan KK, Chan YP, Chua CW, McCrudden CM et al. Prostate cancer cells modulate osteoblast mineralisation and osteoclast differentiation through Id-1. Br J Canc. 2010; 102: 332–41.
   Web of Science ®Google Scholar
• Itoh T, Ito Y, Ohtsuki Y, Ando M, Tsukamasa Y, Yamada N et al. Microvesicles released from hormone-refractory prostate cancer cells facilitate mouse pre-osteoblast differentiation. J Mol Histol. 2012; 43: 509–15. [PubMed Abstract] [PubMed CentralFull Text].
   Google Scholar
• Mundy GR. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Canc. 2002; 2: 584–93.
   PubMed Web of Science ®Google Scholar
• DeMambro VE, Maile L, Wai C, Kawai M, Cascella T, Rosen CJ et al. Insulin-like growth factor-binding protein-2 is required for osteoclast differentiation. J Bone Miner Res. 2012; 27: 390–400. [PubMed Abstract] [PubMed CentralFull Text].
   Google Scholar
• Everts V, Daci E, Tigchelaar-Gutter W, Hoeben KA, Torrekens S, Carmeliet G et al. Plasminogen activators are involved in the degradation of bone by osteoclasts. Bone. 2008; 43: 915–20. [PubMed Abstract].
   Google Scholar
• Irie N, Takada Y, Watanabe Y, Matsuzaki Y, Naruse C, Asano M et al. Bidirectional signaling through ephrinA2-EphA2 enhances osteoclastogenesis and suppresses osteoblastogenesis. J Biol Chem. 2009; 284: 14637–44. [PubMed Abstract] [PubMed CentralFull Text].
   Google Scholar
• Mori K, Miyamoto N, Higuchi Y, Nanba K, Ito M, Tsurudome M et al. Cross-talk between RANKL and FRP-1/CD98 Systems: RANKL-mediated osteoclastogenesis is suppressed by an inhibitory anti-CD98 heavy chain mAb and CD98-mediated osteoclastogenesis is suppressed by osteoclastogenesis inhibitory factor. Cell Immunol. 2001; 207: 118–26. [PubMed Abstract].
   Google Scholar
• Ell B, Mercatali L, Ibrahim T, Campbell N, Schwarzenbach H, Pantel K et al. Tumor-Induced osteoclast miRNA changes as regulators and biomarkers of osteolytic bone metastasis. Cancer Cell. 2013; 24: 542–56. [PubMed Abstract].
   Google Scholar
• Cheng P, Chen C, He HB, Hu R, Zhou HD, Xie H et al. miR-148a regulates osteoclastogenesis by targeting V-maf musculoaponeurotic fibrosarcoma oncogene homolog B. J Bone Miner Res. 2013; 28: 1180–90. [PubMed Abstract].
   Google Scholar
• Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature. 2003; 423: 337–42. [PubMed Abstract].
   Google Scholar
• Theriault RL, Theriault RL. Biology of bone metastases. Canc Contr. 2012; 19: 92–101.
   PubMed Web of Science ®Google Scholar
• Garbe AI, Roscher A, Schuler C, Lutter AH, Glosmann M, Bernhardt R et al. Regulation of bone mass and osteoclast function depend on the F-actin modulator SWAP-70. J Bone Miner Res. 2012; 27: 2085–96. [PubMed Abstract].
   Google Scholar
• Corey E, Quinn JE, Bladou F, Brown LG, Roudier MP, Brown JM et al. Establishment and characterization of osseous prostate cancer models: intra-tibial injection of human prostate cancer cells. Prostate. 2002; 52: 20–33. [PubMed Abstract].
   Google Scholar
• Kalikin LM, Schneider A, Thakur MA, Fridman Y, Griffin LB, Dunn RL et al. In vivo visualization of metastatic prostate cancer and quantitation of disease progression in immunocompromised mice. Canc Biol Ther. 2003; 2: 656–60.
   PubMed Web of Science ®Google Scholar
• Fradet A, Sorel H, Depalle B, Serre CM, Farlay D, Turtoi A et al. A new murine model of osteoblastic/osteolytic lesions from human androgen-resistant prostate cancer. PLoS One. 2013; 8: e75092. [PubMed Abstract] [PubMed CentralFull Text].
   Google Scholar
• Roudier MP, Corey E, True LD, Hiagno CS, Ott SM, Vessell RL. Histological, immunophenotypic and histomorphometric characterization of prostate cancer bone metastases. Canc Treat Res. 2004; 118: 311–39.
   Google Scholar
• Di Vizio D, Morello M, Dudley AC, Schow PW, Adam RM, Morley S et al. Large oncosomes in human prostate cancer tissues and in the circulation of mice with metastatic disease. Am J Pathol. 2012; 181: 1573–84. [PubMed Abstract] [PubMed CentralFull Text].
   Google Scholar
• Morello M, Minciacchi VR, de Candia P, Yang J, Posadas E, Kim H et al. Large oncosomes mediate intercellular transfer of functional microRNA. Cell Cycle. 2013; 12: 3526–36. [PubMed Abstract] [PubMed CentralFull Text].
   Google Scholar
• Escrevente C, Keller S, Altevogt P, Costa J. Interaction and uptake of exosomes by ovarian cancer cells. BMC Canc. 2011; 11: 108.
   PubMed Web of Science ®Google Scholar
• Takahashi Y, Nishikawa M, Shinotsuka H, Matsui Y, Ohara S, Imai T et al. Visualization and in vivo tracking of the exosomes of murine melanoma B16-BL6 cells in mice after intravenous injection. J Biotechnol. 2013; 165: 77–84. [PubMed Abstract].
   Google Scholar
• Chantry AD, Heath D, Mulivor AW, Pearsall S, Baud'huin M, Coulton L et al. Inhibiting activin-A signaling stimulates bone formation and prevents cancer-induced bone destruction in vivo. J Bone Miner Res. 2010; 25: 2633–46. [PubMed Abstract].
   Google Scholar
• De Benedetti F, Rucci N, Del Fattore A, Peruzzi B, Paro R, Longo M et al. Impaired skeletal development in interleukin-6-transgenic mice: a model for the impact of chronic inflammation on the growing skeletal system. Arthritis Rheum. 2006; 54: 3551–63. [PubMed Abstract].
   Google Scholar
• Malpe R, Baylink DJ, Linkhart TA, Wergedal JE, Mohan S. Insulin-like growth factor (IGF)-I, -II, IGF binding proteins (IGFBP)-3, -4, and -5 levels in the conditioned media of normal human bone cells are skeletal site-dependent. J Bone Miner Res. 1997; 12: 423–30. [PubMed Abstract].
   Google Scholar
• Silha JV, Mishra S, Rosen CJ, Beamer WG, Turner RT, Powell DR et al. Perturbations in bone formation and resorption in insulin-like growth factor binding protein-3 transgenic mice. J Bone Miner Res. 2003; 18: 1834–41. [PubMed Abstract].
   Google Scholar
• Adler HL, McCurdy MA, Kattan MW, Timme TL, Scardino PT, Thompson TC. Elevated levels of circulating interleukin-6 and transforming growth factor-beta1 in patients with metastatic prostatic carcinoma. J Urol. 1999; 161: 182–7. [PubMed Abstract].
   Google Scholar
• Leto G, Incorvaia L, Badalamenti G, Tumminello FM, Gebbia N, Flandina C et al. Activin A circulating levels in patients with bone metastasis from breast or prostate cancer. Clin Exp Metastasis. 2006; 23: 117–22. [PubMed Abstract].
   Google Scholar
• Shariat SF, Andrews B, Kattan MW, Kim J, Wheeler TM, Slawin KM. Plasma levels of interleukin-6 and its soluble receptor are associated with prostate cancer progression and metastasis. Urology. 2001; 58: 1008–15. [PubMed Abstract].
   Google Scholar
• Tumminello FM, Badalamenti G, Incorvaia L, Fulfaro F, D'Amico C, Leto G. Serum interleukin-6 in patients with metastatic bone disease: correlation with cystatin C. Med Oncol. 2009; 26: 10–15. [PubMed Abstract].
   Google Scholar
• Blanco MA, LeRoy G, Khan Z, Aleckovic M, Zee BM, Garcia BA et al. Global secretome analysis identifies novel mediators of bone metastasis. Cell Res. 2012; 22: 1339–55. [PubMed Abstract] [PubMed CentralFull Text].
   Google Scholar
• Laitala-Leinonen T, Rinne R, Saukko P, Vaananen HK, Rinne A. Cystatin B as an intracellular modulator of bone resorption. Matrix Biol. 2006; 25: 149–57. [PubMed Abstract].
   Google Scholar
• Chiu KH, Chang YH, Wu YS, Lee SH, Liao PC. Quantitative secretome analysis reveals that COL6A1 is a metastasis-associated protein using stacking gel-aided purification combined with iTRAQ labelling. J Proteome Res. 2011; 10: 1110–25. [PubMed Abstract].
   Google Scholar
• Tumber A, Papaioannou S, Breckon J, Meikle MC, Reynolds JJ, Hill PA. The effects of serine proteinase inhibitors on bone resorption in vitro. J Endocrinol. 2003; 178: 437–47. [PubMed Abstract].
   Google Scholar
• Achbarou A, Kaiser S, Tremblay G, Ste-Marie LG, Brodt P, Goltzman D et al. Urokinase overproduction results in increased skeletal metastasis by prostate cancer cells in vivo. Canc Res. 1994; 54: 2372–7.
   PubMed Web of Science ®Google Scholar
• Lehmann U, Hasemeier B, Christgen M, Muller M, Romermann D, Langer F et al. Epigenetic inactivation of microRNA gene hsa-mir-9-1 in human breast cancer. J Pathol. 2008; 214: 17–24. [PubMed Abstract].
   Google Scholar
• Katada T, Ishiguro H, Kuwabara Y, Kimura M, Mitui A, Mori Y et al. microRNA expression profile in undifferentiated gastric cancer. Int J Oncol. 2009; 34: 537–42. [PubMed Abstract].
   Google Scholar
• Lujambio A, Calin GA, Villanueva A, Ropero S, Sanchez-Cespedes M, Blanco D et al. A microRNA DNA methylation signature for human cancer metastasis. Proc Natl Acad Sci Unit States Am. 2008; 105: 13556–61.
   PubMed Web of Science ®Google Scholar
• Murata T, Takayama K, Katayama S, Urano T, Horie-Inoue K, Ikeda K et al. miR-148a is an androgen-responsive microRNA that promotes LNCaP prostate cell growth by repressing its target CAND1 expression. Prostate Cancer Prostatic Dis. 2010; 13: 356–61. [PubMed Abstract].
   Google Scholar
• Fujita Y, Kojima K, Ohhashi R, Hamada N, Nozawa Y, Kitamoto A et al. MiR-148a attenuates paclitaxel resistance of hormone-refractory, drug-resistant prostate cancer PC3 cells by regulating MSK1 expression. J Biol Chem. 2010; 285: 19076–84. [PubMed Abstract] [PubMed CentralFull Text].
   Google Scholar
• Li ZG, Yang J, Vazquez ES, Rose D, Vakar-Lopez F, Mathew P et al. Low-density lipoprotein receptor-related protein 5 (LRP5) mediates the prostate cancer-induced formation of new bone. Oncogene. 2008; 27: 596–603. [PubMed Abstract].
   Google Scholar
• Schulze J, Albers J, Baranowsky A, Keller J, Spiro A, Streichert T et al. Osteolytic prostate cancer cells induce the expression of specific cytokines in bone-forming osteoblasts through a Stat3/5-dependent mechanism. Bone. 2010; 46: 524–33. [PubMed Abstract].
   Google Scholar
• Koumangoye RB, Sakwe AM, Goodwin JS, Patel T, Ochieng J. Detachment of breast tumor cells induces rapid secretion of exosomes which subsequently mediate cellular adhesion and spreading. PLoS One. 2011; 6: e24234. [PubMed Abstract] [PubMed CentralFull Text].
   Google Scholar
• Parolini I, Federici C, Raggi C, Lugini L, Palleschi S, De Milito A et al. Microenvironmental pH is a key factor for exosome traffic in tumor cells. J Biol Chem. 2009; 284: 34211–22. [PubMed Abstract] [PubMed CentralFull Text].
   Google Scholar
• Webber J, Steadman R, Mason MD, Tabi Z, Clayton A. Cancer exosomes trigger fibroblast to myofibroblast differentiation. Canc Res. 2010; 70: 9621–30.
   PubMed Web of Science ®Google Scholar